PulseAugur
LIVE 12:30:00
research · [2 sources] ·
0
research

AI benchmark tackles pancreatic cancer vascular invasion with uncertainty-aware models

By PulseAugur Editorial · Summary by gemini-2.5-flash-lite from 2 sources

Researchers have introduced the CURVAS-PDACVI Dataset and Challenge, an open benchmark designed to improve AI's ability to assess vascular invasion in pancreatic ductal adenocarcinoma (PDAC). This benchmark addresses the lack of public datasets and the inherent ambiguity in identifying tumor extension into vessels, which often leads to variability among expert radiologists. The dataset includes five expert annotations per scan, and the evaluation framework considers probabilistic calibration alongside spatial overlap, highlighting that current methods often struggle with high-complexity cases and uncertain boundaries. AI

Summary written by gemini-2.5-flash-lite from 2 sources. How we write summaries →

IMPACT This benchmark could lead to more reliable AI tools for surgical planning in PDAC by addressing uncertainty and inter-rater variability.

RANK_REASON The cluster describes a new benchmark and dataset for AI in medical imaging, which falls under research.

Read on arXiv cs.CV →

COVERAGE [2]

  1. arXiv cs.CV TIER_1 · M. Riera-Mar\'in, O. K. Sikha, J. Rodr\'iguez-Comas, M. S. May, T. Kirscher, X. Coubez, P. Meyer, S. Faisan, Z. Pan, X. Zhou, X. Liang, C. H\'emon, V. Boussot, J. -L. Dillenseger, J. -C. Nunes, K. -C. Kahl, C. L\"uth, J. Traub, P. -H. Conze, M. M. Duh, A. ·

    Assessing Pancreatic Ductal Adenocarcinoma Vascular Invasion: the PDACVI Benchmark

    arXiv:2604.27582v1 Announce Type: new Abstract: Surgical resection remains the only potentially curative treatment for pancreatic ductal adenocarcinoma (PDAC), and eligibility depends on accurate assessment of vascular invasion (VI), i.e., tumor extension into adjacent critical v…

  2. arXiv cs.CV TIER_1 · A. Galdran ·

    Assessing Pancreatic Ductal Adenocarcinoma Vascular Invasion: the PDACVI Benchmark

    Surgical resection remains the only potentially curative treatment for pancreatic ductal adenocarcinoma (PDAC), and eligibility depends on accurate assessment of vascular invasion (VI), i.e., tumor extension into adjacent critical vessels. Despite its importance for preoperative …

RELATED ENTITIES

RELATED TOPICS